Hikma Pharmaceuticals PLC 2011 AR2
The report highlights Hikma Pharmaceuticals PLC's performance in 2011, during which the company achieved strong revenue growth of 25.6% to $918.0 million. Key milestones included the acquisition of Baxter Healthcare's US Multi-Source Injectables business, doubling the size of its global Injectables business, and entering the Moroccan market through the acquisition of Promopharm. In sustainability, Hikma renewed its ISO 14001:2004 environmental management certification in Jordan and Egypt, and submitted its third Communication on Progress to the UN Global Compact. The company also made strategic investments in India and China to strengthen its API sourcing and R&D capabilities.
Company: Hikma Pharmaceuticals PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2011
Type: AR2
Pages: 156
Hikma Pharmaceuticals PLC
The report highlights Hikma Pharmaceuticals PLC's performance in 2011, during which the company achieved strong revenue growth of 25.6% to $918.0 million. Key milestones included the acquisition of Baxter Healthcare's US Multi-Source Injectables business, doubling the size of its global Injectables business, and entering the Moroccan market through the acquisition of Promopharm. In sustainability, Hikma renewed its ISO 14001:2004 environmental management certification in Jordan and Egypt, and submitted its third Communication on Progress to the UN Global Compact. The company also made strategic investments in India and China to strengthen its API sourcing and R&D capabilities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2011
Reporting Period
Jan 1, 2011 - Dec 31, 2011
Fiscal Year
2011
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Employees